Sorry, you need to enable JavaScript to visit this website.
Modification of epigenetic signaling has the potential to serve as a new route in to the treatment of human diseases, including a range of chronic and life-threatening conditions. Epigenomic profiling may form a component of successful Precision Medicine strategies, for conditions with epigenetic and non-epigenetic treatments. Epigenetic modifications are also key mediators of cell fate, with implications for cellular therapies using reprogrammed somatic cells.

WRD is interested in establishing alliances to develop and access:

  • Epigenetic targets with a high degree of biological validation
  • Novel compounds with epigenetic mechanisms of action
  • Epigenomic biomarkers

Specific areas of interest include:

  • Validated epigenetic targets with strong mechanism of action support in chronic and life-threatening conditions
  • Applications for epigenetically targeted compounds in orphan diseases and genetic conditions
  • Epigenomic biomarkers for disease stratification, progression or treatment sensitivity
  • Novel epigenetically-targeted compounds with known mechanism of action and defined patient populations
  • Selective HDAC inhibitors

Not actively seeking partnering opportunities in:

  • Pre-clinical DNA methyltransferase inhibitors for oncology
  • Pre-clinical pan-HDAC inhibitors
  • Non-coding RNAs (microRNAs, etc.) as systemic therapeutic agents